Annals of Thoracic Medicine
: 2010  |  Volume : 5  |  Issue : 4  |  Page : 201--216

Imaging lung manifestations of HIV/AIDS

Carolyn M Allen1, Hamdan H AL-Jahdali2, Klaus L Irion3, Sarah Al Ghanem2, Alaa Gouda2, Ali Nawaz Khan1,  
1 North Manchester General Hospital, Pennine Acute NHS Trust, Manchester, United Kingdom
2 King Fahad Hospital King Abdulaziz Medical City, Riyadh, Saudi Arabia
3 The Cardiothoracic Centre Liverpool NHS Trust, The Royal Liverpool University Hospital, United Kingdom

Correspondence Address:
Ali Nawaz Khan
North Manchester General Hospital, Pennine Acute NHS Trust Crumpsall, Manchester M8 6RB
United Kingdom


Advances in our understanding of human immunodeficiency virus (HIV) infection have led to improved care and incremental increases in survival. However, the pulmonary manifestations of HIV/acquired immunodeficiency syndrome (AIDS) remain a major cause of morbidity and mortality. Respiratory complaints are not infrequent in patients who are HIV positive. The great majority of lung complications of HIV/AIDS are of infectious etiology but neoplasm, interstitial pneumonias, Kaposi sarcoma and lymphomas add significantly to patient morbidity and mortality. Imaging plays a vital role in the diagnosis and management of lung of complications associated with HIV. Accurate diagnosis is based on an understanding of the pathogenesis of the processes involved and their imaging findings. Imaging also plays an important role in selection of the most appropriate site for tissue sampling, staging of disease and follow-ups. We present images of lung manifestations of HIV/AIDS, describing the salient features and the differential diagnosis.

How to cite this article:
Allen CM, AL-Jahdali HH, Irion KL, Al Ghanem S, Gouda A, Khan AN. Imaging lung manifestations of HIV/AIDS.Ann Thorac Med 2010;5:201-216

How to cite this URL:
Allen CM, AL-Jahdali HH, Irion KL, Al Ghanem S, Gouda A, Khan AN. Imaging lung manifestations of HIV/AIDS. Ann Thorac Med [serial online] 2010 [cited 2022 Jan 19 ];5:201-216
Available from:

Full Text

Human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) remains a critical world health issue and is a major cause of morbidity and mortality. More than 25 million people have died of AIDS since 1981. Africa has 11.6 million AIDS orphans. [1]

The lungs are one of the chief target organs for HIV-associated disease, and almost 70% of the patients suffer at least one respiratory complication during the course of their illness. [2],[3],[4] In the HIV patient, there is an enhanced prevalence of bronchial hyperresponsiveness and dysfunction of the small airways. [5],[6]

Recently gained knowledge of the immunologic impact of HIV on disease progression has led to better care and incremental increase in survival. Better prophylaxis for opportunistic infections and the development of highly active antiretroviral therapy (HAART) has had a significant impact against HIV. HAART has had a significant impact on viral load, CD 4+ cell count and HIV-related mortality both in adults [7] and in pediatric populations [8] (75% and 67% reductions, respectively, in the risk of death with HAART). [8] Similar reductions in the incidence of both community-acquired pneumonia[9] and opportunistic infections, including Mycobacterium tuberculosis (MTB), cytomegalovirus (CMV) and Pneumocystis carinii pneumonia (PCP), have been recently reported with HAART. [2],[7],[10],[11]

Coupled with the wide spectrum of pulmonary diseases encountered in AIDS summarized in [Table 1], this poses a considerable challenge for the radiologist and the attending physician. It is therefore imperative that we use an integrated approach in the interpretation of imaging. Pattern recognition should be combined with knowledge of clinical factors in order to generate a limited and meaningful differential diagnosis [Table 2]. For example, Kaposi sarcoma (KS) is seen almost exclusively in homosexual and bisexual men and their partners [12],[13],[14] whereas IV drug abusers are particularly prone to bacterial infections and MTB. [15],[16]{Table 1}{Table 2}

A productive cough is distinctly atypical for PCP and should suggest pyogenic infection, whereas miliary nodularity may reflect disseminated fungal infection or tuberculosis (TB) in a sick patient. In a relatively well patient, it likely represents a more indolent process such as lymphoproliferative disorder. [17],[18],[19],[20],[21],[22],[23]

Steroids may increase the degree of immune suppression and HAART can lead to various manifestations of immune restoration syndrome. [24] A history of previous opportunistic infection has been shown to increase the risk of a further episode, even when other factors such as the CD4 level are taken into account. [25]

However, the level of immune compromise is the most important determinant in assessing the likelihood of various pulmonary complications. This is reflected in the CD4 count, with specific diseases occurring with increasing frequency as certain CD4 thresholds are reached. At CD4 levels above 400, patients are at risk of infection from relatively virulent organisms, such as bacteria and TB. Lung cancer may also occur at this stage. Between counts of 200 and 400, patients may suffer from recurrent infection as well as lymphoma. Opportunistic infections and KS are rare at CD4 levels >200 and indeed most cases of PCP occur at CD4 counts below 100, along with Mycobacterium avium complex (MAC), fungal infections and CMV [26] [Table 2].

The conventional chest X-ray (CXR) is usually the first line and often only imaging investigation. Despite the variety of differential diagnoses, overlapping features, atypical manifestations and multifactorial disease, the CXR is accurate for diagnosing common complications, with reported accuracies of 64%, 75% and 84% for diagnosing bacterial pneumonia, PCP and MTB, respectively, in a blinded trial. [27]

High-resolution computed tomography (HRCT) is both more sensitive and more accurate, with an overall diagnostic accuracy of 92%, including 90% for KS and 94% for PCP. Furthermore, CT has a useful 93% negative predictive value in excluding active pulmonary disease.

When comparing CXR and HRCT, Kang found that a confident diagnosis was made more often on CT than on CXR, and this confident diagnosis was more often correct on CT than on CXR. The correct confident interpretation was made more often in patients with lymphoma (100%), KS (91%) and PCP (87%). [28] However, CT only affords a modest improvement and is therefore not routinely indicated [29 ] [Table 3]. Specific indications include the detection of occult disease in symptomatic patients, characterizing nonspecific radiographic disease patterns, assessment of the mediastinum, staging malignancy, assessing complications (particularly pleural disease) and guiding invasive procedures.{Table 3}

 Clinical and Radiologic Manifestation

Clinical findings vary with the degree of immune suppression, ranging from an increased incidence of bronchitis and sinusitis, with CD4 counts above 500/΅L, to PCP and KS, with CD4 counts below 200/΅L. [4] The introduction of HAART has succeeded in considerable reduction in mortality from AIDS in both adult and pediatric populations. [7],[8] A similar reduction has been achieved in the incidence of both community and acquired pneumonia. [2],[7],[9],[10],[11]

 Bacterial Infection

Infections are the most common pulmonary complication of AIDS, and bacteria are the most common cause of infection, superseding PCP at all levels of immune compromise.

Multiorganism infection is common, involving Streptococcus pneumoniae, Hemophilus influenzae, Pseudomonas and Staphylococcus aureus. Infection is frequently not pneumonic, the most common manifestation being acute bronchitis/bronchiolitis. [30],[31],[32] Patients with bacterial pneumonia typically present with an acute onset of fever and productive cough. [33]

The CXR in bacterial bronchiolitis may be normal or may reveal bilateral symmetrical lower lobar bronchial wall thickening appearing as ring shadows and "tram-tracks" [34] [Figure 1]. Abnormalities may be detected on HRCT in the absence of any CXR findings [Figure 1]. These include bronchiectasis and evidence of small airway disease, with ill-defined centrilobular micronodularity and branching structures or tree-in-bud appearance secondary to mucus impaction in the bronchioles. Mosaic attenuation may also be present due to air trapping. [34]{Figure 1}

The typical radiographic appearance of bacterial pneumonia CXR in AIDS is the same as that in an immune competent host with lobar or segmental consolidation but progressing rapidly, with frequent multilobar or bilateral disease [27],[35],[36] [Figure 2]. Parapneumonic effusions and empyema are common. Cavitation may occur, [35],[36] particularly with septic emboli and gram-negative infection [Figure 3] and [Figure 4]. A useful ancillary finding is the identification of a characteristic feeding vessel (arrow) on CT [Figure 4]. Although pyogenic infections are the most common cause of these imaging findings in AIDS patients, viral and mycobacterial infections may produce similar appearances. [34]{Figure 2}{Figure 3}{Figure 4}


P. carinii remains the most common opportunistic and most common life-threatening pulmonary infection in AIDS. [37],[38],[39] PCP usually occurs in patients not receiving medical care. [40],[41] Radiographic changes are varied and may lag behind the symptoms. [40] The classic appearance is of bilateral symmetric perihilar or diffuse interstitial opacification, which may be reticular, finely granular or ground-glass in appearance [40] [Figure 5],[Figure 6],[Figure 7]. If left untreated, this may progress to alveolar consolidation in 3 or 4 days. Infiltrates clear within 2 weeks but in a proportion, infection will be followed by coarse reticular opacification and fibrosis [40] [Figure 8] and [Figure 9].{Figure 5}{Figure 6}{Figure 7}{Figure 8}{Figure 10}

HRCT is more sensitive, the hallmark being ground-glass attenuation, seen in over 90% of the cases. It often has a geographic or mosaic distribution. In this clinical setting, this is virtually diagnostic of PCP and is sufficient for commencement of empirical treatment [40] [Figure 10] and [Figure 11]. Foci of consolidation and interlobular septal thickening may be seen in the subacute stage due to organized inflammatory infiltrate [40] [Figure 10] and [Figure 11].{Figure 11}

Cystic lung disease is a relatively common manifestation. [35],[40] Cysts are usually multiple and bilateral, but range in size, shape and distribution [35],[40] [Figure 12]. They may develop in the acute or postinfective period and have been reported to remain for up to 3 years. They are more commonly appreciated on CT/HRCT, being reported in up to one-third of the patients [Figure 13].{Figure 12}{Figure 13}

Spontaneous pneumothorax is a well-recognised complication, particularly in patients with cysts [Figure 14]. Pneumothoraces may be bilateral and they have important implications for management and prognosis as patients have a significantly increased mortality rate [Figure 15] and [Figure 16]. Pneumothoraces are often refractory to conventional chest tube drainage, becoming chronic and requiring pleurodesis or surgical intervention [40] [Figure 17].{Figure 14}{Figure 15}{Figure 16}{Figure 17}

The CXR may be normal in 10%, although this is uncommon in clinical practice [40],[42] Atypical findings are seen in a further 10%, including isolated focal or asymmetrical dense consolidation, airways disease and adenopathy. Effusions are extremely uncommon and should prompt the search for other pathogens. Nodules are another unusual manifestation. Histologically, these represent granulomas. Nodules can vary from miliary to >1 cm in size, and may infrequently undergo cavitation or calcification [35],[40] [Figure 18],[Figure 19],[Figure 20],[Figure 21],[Figure 22].{Figure 18}{Figure 19}{Figure 20}{Figure 21}{Figure 22}

 Mycobacterial Infections

MTB is the most common pulmonary complication of HIV worldwide. [43] Making the diagnosis may be difficult as patients tend to be anergic. Therefore, imaging has an important role to play in the diagnosis. [43],[44],[45]

The radiographic appearance of TB in AIDS differs from that in immune competent hosts, with more diffuse and lower zone disease, miliary disease and adenopathy as well as an increased incidence of a normal CXR. [44],[45]

The radiographic appearance generally reflects the CD4 count. When the CD4 level exceeds 200, the appearance is commonly that of typical reactivation MTB in a previously infected immune competent host. Classical primary TB can also be seen in patients without prior exposure. In contrast, patients with CD4 levels below 200 present with a pattern of primary TB, regardless of prior exposure. [43],[44],[45]

Features of reactivation MTB are patchy consolidation, including involvement at unusual sites, e.g. lower lobes, cavitation, nodularity, effusions and adenopathy [Figure 23]. TB lymph nodes are typically markedly enlarged and of low attenuation on CT, often demonstrating rim enhancement following contrast administration [43],[44],[45] [Figure 24].{Figure 23}{Figure 24}

"Primary" MTB manifests as focal unilateral, often lower lobe consolidation and adenopathy [46] [Figure 25]. Cavitation is less common at lower CD4 counts. Patients in this range also have an increased incidence of miliary MTB, with diffuse, randomly distributed nodules on CT [Figure 26]. Approximately 15% of the patients have normal CXRs. [44] This particularly occurs when disease is isolated to the airways. Alternatively, the CXR may demonstrate an asymmetric reticulonodular pattern. However, the HRCT is invariably abnormal, typically demonstrating adenopathy and the "tree-in-bud" pattern, similar to bacterial bronchiolitis [45] [Figure 27]. However, this is usually asymmetric and involves upper as well as lower lobes in distinction to bacterial infection.{Figure 25}{Figure 26}{Figure 27}

Serial CXRs are useful for monitoring response to treatment. [43],[44],[45] A paradoxical response to treatment with transient worsening of appearances within 1 month of commencing anti-TB therapy is a recognized phenomenon. [47] This is more frequent in AIDS patients receiving HAART due to increased inflammatory responses secondary to improved host immunity. Severe worsening may occur, particularly in advanced immune suppression. [47]

Although the time frame and clinical context of immune restoration syndrome are characteristic, radiographic findings are nonspecific, and this should only be diagnosed when other causes, such a poor compliance with treatment, drug resistance, drug reaction and concurrent disease, have been excluded. The latter, in particular, because almost 30% of the patients have been shown to develop new HIV-related lung disease during the first 3-6 months of TB treatment, most commonly PCP. [47]

 Nontuberculous/Atypical Mycobacterium (NTMB)

MAC is the most common atypical mycobacterial infection. [35],[47],[48] It usually causes disseminated disease with pulmonary involvement in only 5%. [35],[47],[48] Clinically significant pneumonia is uncommon and the CXR is often normal, even if sputum cultures are positive. [35],[47],[48] Radiographic abnormalities resemble MTB, with focal consolidation, diffuse patchy infiltrates with upper lobe predominance, nodules and cavities [Figure 28],[Figure 29],[Figure 30]. The features are, however, nonspecific and the diagnosis is often delayed. [35],[47],[48]{Figure 28}{Figure 29}{Figure 30}


Cryptococcus is the fourth most common opportunistic infection in AIDS. [35],[48] The lungs are the portal of entry and the most common site of infection although, the common clinical presentation is with meningitis, pneumonia occurring in only approximately 30%. [35],[48] Imaging findings are varied and nonspecific. Reticular or reticulonodular infiltrates are the most common pattern [35],[49] [Figure 31]. Solitary or multiple nodules [Figure 32], often up to 4 cm in diameter, are seen in around 30%. Biopsy is usually required for diagnosis. Cavitation occurs less frequently in AIDS-related disease compared to immune competent hosts, usually appearing early in the course of the illness, when the level of immune suppression is mild [35],[49],[50] [Figure 33] and [Figure 34]. Less-frequent manifestations include adenopathy, effusions, consolidation, miliary nodularity and ground-glass opacification and chest wall abscesses [35],[49] [Figure 35].{Figure 31}{Figure 32}{Figure 33}{Figure 34}{Figure 35}


Aspergillosis occurs almost exclusively in association with neutropoenia, usually secondary to drug therapy. [35],[50] The incidence is reported to be around 1%, but is thought to be increasing due to prolonged survival at advanced levels of immune suppression. [50] All forms have been described, often coexisting in the same patient. Mycetomas are the least common, but can complicate cavitary MTB or PCP [35],[50] [Figure 36]. Clinical progression to invasive Aspergillosis is reported to occur in 50%, despite antifungal therapy, whereas this is not a feature of the disease in immune competent hosts. Angioinvasive disease is most common, manifest as thick-walled cavitary lesions predominating in the upper lobes, with air-crescents surrounding areas of desquamated infarcted lung [35],[50] [Figure 37] Less-common patterns include nodules with a peripheral halo of ground-glass attenuation and isolated airway disease [Figure 38] or Allergic bronchopulmonary Aspergillosis (ABPA), manifesting as bilateral lower lobe consolidation, bronchiectasis and airway impaction or "finger in glove" [35],[50] [Figure 39] and [Figure 40].{Figure 36}{Figure 37}{Figure 38}{Figure 39}{Figure 40}


Ninety percent of HIV-positive patients are thought to carry latent CMV infection, although it is not considered a significant pulmonary pathogen in the majority. [35] CMV pneumonitis is thought to be increasing in incidence likely secondary to enhanced life expectancy and changing demographics with increased heterosexual HIV transmission, which is associated with CMV infection. [35]

The spectrum of radiographic findings is varied and overlaps other AIDS-related diseases, most notably PCP. [35] Features include ground-glass opacification, nodules (varying from miliary to 3 cm), perihilar and lower zone interstitial infiltrates and effusions. When ground-glass opacification is associated with nodularity and an effusion, CMV should be considered over PCP, especially in patients with CD4 counts below 50. [51] Small airway disease may be the sole manifestation of infection [51] [Figure 41] and [Figure 42].{Figure 41}{Figure 42}


KS is by far the most common AIDS-related malignancy. [35] The male:female ratio is 50:1. [35] KS Herpes virus or Human Herpes virus 8 has been identified as the probable cause, likely in conjunction with cofactors. [35],[36],[37],[38],[39],[40],[41],[42],[43],[44],[45],[46],[47],[48],[49],[50],[51],[52] Pulmonary involvement occurs in up to 50% and is almost always preceded by cutaneous or visceral disease, although the latter may not always be recognized. [53]

Bilateral, perihilar and lower-zone reticulonodular infiltrates are characteristic [Figure 43]. Septal lines may also be visible. "Flame-shaped" nodules or masses are another characteristic finding classically associated with a halo of ground-glass attenuation on CT [35],[42] [Figure 44]. Although adenopathy has been described, this is rarely significant, and while endobronchial lesions are identified in up to 75% of the patients bronchoscopically, they are less commonly appreciated on CT. [35],[42]{Figure 43}{Figure 44}

Thickening of bronchovascular bundles reflecting the bronchocentric distribution of disease is demonstrated on HRCT. Interlobular septal thickening due to lymphatic obstruction and tumor invasion is also seen [35],[42],[54] [Figure 44]. Pleural effusions are common, present in around 30%. They may be unilateral or bilateral and may be large and characteristically hemorrhagic on aspiration [35],[42],[54] [Figure 45].{Figure 45}


AIDS-related lymphoma (ARL) is the second most common malignancy. [52],[55] The incidence is increasing, possibly due to the longer life expectancy coupled with the longer latency period required for the development of neoplasms. [56]

Non-Hodgkin's Lymphoma (NHL) accounts for 90% and the majority of cases are associated with Epstein-Barr virus. NHL is typically extranodal and usually disseminated at the time of diagnosis. [52] Thoracic involvement is reported in up to 40%, although subclinical involvement is probably higher. [52],[57]

Well-defined solitary or multiple parenchymal nodules are common [Figure 46]. These are frequently large and often demonstrate a very short doubling time of between 4 and 6 weeks, mimicking infection. Unlike KS, they are often peripheral and while air-bronchograms may be seen, cavitation is unusual [55],[57] [Figure 47].{Figure 46}{Figure 47}

Lymphadenopathy is a less common feature in AIDS-related NHL, and nodes are rarely significant according to size criteria. Effusions are common, may be unilateral or bilateral and are usually moderate to large in size. [58]

A rare form of ARL, called body cavity lymphoma, has been described, usually affecting homosexual males with advanced AIDS, manifest as pleural, pericardial or peritoneal effusions in the absence of any soft tissue tumor. [59],[60],[61]

 Lung Carcinoma

There is conflicting data regarding the incidence of lung carcinoma in AIDS and, to date, there is no convincing evidence showing a significant rise. [56],[58],[62] It occurs in smokers, although important clinical differences have been noted compared with the general population. [58] There is a striking male preponderance and patients often present at a younger age and at a later stage. [58],[62] There is no correlation between stage of disease and CD4 count. Tumors are frequently poorly differentiated or predominantly adenocarcinomas. [58],[63] Radiographic appearances are similar to ordinary lung cancer, except that lesions tend to be more peripheral, with over 90% in the upper lobes. [58],[64] Extensive pleural disease as the sole radiographic manifestation of lung cancer has also been reported [58],[64] [Figure 48].{Figure 48}

 Lymphoproliferative Disorders

A spectrum of polyclonal lymphoproliferative disorders affects the lungs of HIV-positive patients, the most common being lymphocytic interstitial pneumonitis. [35],[65] This is thought to represent lymphoid hyperplasia in response to chronic antigenic stimulation by the AIDS virus. [35],[65] It is far more common in children than in adults. [66] The diagnosis is made on transbronchial biopsy. On CT, there is smooth and nodular thickening of bronchovascular bundles, centrilobular and subpleural nodularity, ground-glass opacification and interlobular septal thickening. [65],[67],[68] Cysts and mediastinal adenopathy may also be seen [68] [Figure 49] and [Figure 50].{Figure 49}{Figure 50}

 Bronchiolitis Obliterans

Bronchiolitis obliterans, with or without organizing pneumonia in the absence of infection, can be a feature of AIDS. [69],[70],[71],[72] This is an infrequent imaging diagnosis, although focal air trapping on expiratory CT, consistent with bronchiolitis obliterans, has been demonstrated in two-thirds of HIV-positive patients without AIDS, the severity increasing with the duration of infection. [73] However, because definitive diagnosis requires lung biopsy, the true incidence of disease is unknown and, in clinical practice, the diagnosis is usually one of exclusion. The radiographic appearance is as for non-AIDS [73] [Figure 51].{Figure 51}


Recently, work suggests that there may be a higher incidence of pulmonary emphysema among HIV-positive smokers. [71] The probable cause may lie in the susceptibility of HIV patients to recurrent chest infections [71] [Figure 52].{Figure 52}

 Cardiovascular Complications

Better prophylaxis for opportunistic infections and the development of HAART has had a significant impact against HIV on viral load, CD4 + cell count and HIV-related mortality in HIV patients. [7] With longer survival, cardiovascular complications are becoming manifest in these patients. Cardiovascular complications of HIV include cardiomyopathy and pulmonary arterial hypertension [Figure 53]. A higher incidence of atherosclerosis has been reported possibly secondary to protease inhibitor therapies. [74] A recent study lists HIV as a risk factor for deep venous thrombosis and pulmonary embolism [75] [Figure 54]. Finally, a couple of cases do not fit into the categories already described, including mediastinal vascular complications [Figure 55]. Lastly, it would be difficult to predict the biopsy-proven diagnosis in patients with ill-defined centrilobular nodules and confluent mass-like areas of consolidation without knowing that they were hemophiliac and had AIDS [Figure 56].{Figure 53}{Figure 54}{Figure 55}{Figure 56}

 Radiographic Patterns

Limitations reflecting overlapping appearances, atypical manifestations and coexisting disease contribute to a relative lack of specificity of imaging. However, certain basic radiographic patterns can be recognized, which should raise the suspicion of certain underlying disease processes.


Pulmonary nodules are a relatively common manifestation of AIDS-related pulmonary disease. The authors of two recent studies categorized nodules according to size and distribution and showed that nodules smaller than 1 cm, especially those with a random or centrilobular distribution, are more likely to be due to infection (infections being the most common overall cause of multiple nodules), whereas nodules larger than 1 cm are more likely neoplastic. Miliary nodularity is typically due to fungal infection or TB, although, rarely, it may be seen with PCP. KS tends to be peribronchovascular as opposed to lymphoma and lung cancer, which are more peripheral. [76]


Another study showed that cavitating lesions were universally infective in etiology. Eighty-five percent were polymicrobial, the majority involving bacteria (predominantly due to mixed infections often involving Staphylococcus and Pseudomonas). The remainder included MTB, PCP, fungi and CMV. [77],[78],[79],[80],[81]


Adenopathy is also most commonly due to infection. Although isolated lymphadenopathy can be seen in association with Cryptococcus, TB is by far the most common cause, accounting for about 85% of the cases. Both may be associated with low attenuation adenopathy. Lung cancer should also be included in the differential diagnosis. Calcified adenopathy has been described in PCP. KS may be associated with hyperattenuating lymphadenopathy due to vascular enhancement. This has been shown to have a 70% PPV. [82]

 Focal Consolidation

This is usually due to infection. A report in clinical radiology identified bacterial pneumonia as the most common cause of focal consolidation in AIDS, but showed that Pneumocystis was the most common individual pathogen to cause the appearance, usually as an upper lobe infiltrate. Consolidative PCP, however, rarely has a segmental pattern, helping in distinguishing it from bacterial infection. MTB, MAC, fungi (especially Cryptococcus), mixed infections and, rarely, neoplasms such as lymphoma and KS may also be responsible. [67],[83],[84]

 Pleural Effusion

The majority of effusions in AIDS are small, occurring with equal incidence in both infection and malignancy. The three main causes are bacterial infection, MTB and KS. Infective causes tend to be associated with unilateral effusions whereas those in KS tend to be bilateral. Non-AIDS-related conditions such as pulmonary embolism (PE) and organ failure should also be considered. [57],[60],[85],[86],[87]


Despite the development of effective antiviral therapies and better prophylaxis of opportunistic infections, pulmonary complications of HIV/AIDS remain an important cause of morbidity and mortality. We have provided a pictorial assay of the lung afflictions seen in HIV/AIDS and have discussed the interpretation of imaging studies based on pattern recognition read in conjunction with demographic, clinical and laboratory data. Presently, a CXR remains the mainstay of thoracic imaging in HIV-infected patients, but CT/HRCT plays an increasingly important complementary role in establishing an accurate diagnosis when CXR findings are equivocal or nonspecific.


1The latest statistics on the world epidemic of HIV and AIDS were published by UNAIDS/WHO in July 2008, and refer to the end of 2007.
2Beck JM, Rosen MJ, Peavy HH. Pulmonary complications of HIV infection: Report of the Fourth NHLBI Workshop. Am J Respir Crit Care Med 2001;164:2120-6.
3Taylor IK, Coker RJ, Clarke J, Moss FM, Nieman R, Evans DJ,et al. Pulmonary complications of HIV disease: 10-year retrospective evaluation of yields from bronchoalveolar lavage, 1983-93. Thorax 1995;50:1240-5.
4Rosen MJ. Overview of pulmonary complications. Clin Chest Med 1996;17:621-31.
5Poirier CD, Inhaber N, Lalonde RG, Ernst P. Prevalence of bronchial hyperrsponsiveness among HIV-infected men. Am J Respir Crit Care Med 2001;164:542-5.
6Fleischman JK, Greenberg H, Web A. Small airways dysfunction in patients with AIDS and Pneumocystis carinii pneumonia. AIDS Patient Care STDS 1996;10:16-20.
7Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study. N Engl J Med 1998;338:853-60.
8Gortmaker SL, Hughes M, Cervia J, Brady M, Johnson GM, Seage GR 3rd, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001;345:1522-8.
9Sullivan JH, Moore RD, Keruly JC, Chaisson RE. Effect of antiretroviral therapy on the incidence of bacterial pneumonia in patients with advanced HIV infection. Am J Respir Crit Care Med 2000;162:64-7.
10Public Health Service, Depart of Health and Human Services, CDCHIV/AIDS Surveillance Report 2002;13:1-41, Joint United Nations Programme on HIV/AIDS/World Health Organization.
11AIDS Epidemic Update. Joint publication of WHO and UNAIDS ISBN 92 9173 132 3. Dec 2001.
12Haramati LB, Jenny-Avital ER. Approach to the diagnosis of pulmonary disease in patients infected with the human immunodeficiency virus. J Thorac Imaging 1998;13:247-60.
13Katariya K, Thurer RJ. Thoracic malignancies associated with AIDS. Semin Thorac Cardiovasc Surg 2000;12:148-53.
14Holemans JA, Howlett DC, Ayers AB. Imaging the thoracic manifestations of AIDS. Hosp Med 1998;59:352-8.
15Lamb RJ, Yeh IT. Tuberculosis, AIDS, and i.v. drug abuse. N J Med 1990;87:413-5.
16Healy E, Kelly P, Mulcahy FM, Clancy L. AIDS, i.v. drug use and mycobacterial disease: The Dublin experience. Respir Med 1992;86:491-4.
17Wollschlager CM, Khan FA, Chitkara RK, Shivaram U. Pulmonary manifestations of the acquired immunodeficiency syndrome (AIDS). Chest 1984;85:197-202.
18Suster B, Akerman M, Orenstein M, Wax MR. Pulmonary manifestations of AIDS: Review of 106 episodes. Radiology 1986;161:87-93.
19Sider L, Weiss AJ, Smith MD, VonRoenn JH, Glassroth J. Varied appearance of AIDS-related lymphoma in the chest. Radiology 1989;171:629-32.
20McLoud TC, Naidich DP. Thoracic disease in the immunocompromised patient. Radiol Clin North Am 1992;30:525-54.
21McAdams HP, Rosado-de-Christenson ML, Lesar M, Templeton PA, Moran CA. Thoracic mycoses from endemic fungi: Radiologic-pathologic correlation. Radiographics 1995;15:255-70.
22Khalil AM, Carette MF, Cadranel JL, Mayaud CM, Bigot JM. Intrathoracic Kaposi's sarcoma. CT findings. Chest 1995;108:1622-6.
23Edinburgh KJ, Jasmer RM, Huang L, Reddy GP, Chung MH, Thompson A, et al. Multiple pulmonary nodules in AIDS: Usefulness of CT in distinguishing among potential causes. Radiology 2000;214:427-32.
24Tavel JA, Sereti I, Walker RE, Hahn B, Kovacs JA, Jagannatha S, et al. A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus. J Infect Dis 2003;188:531-6.
25Helweg-Larsen J, Benfield TL, Eugen-Olsen J, Lundgren JD, Lundgren B. Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. Lancet 1999;354:1347-51.
26Hanson DL, Chu SY, Farizo KM, Ward JW. Distribution of CD4+ T lymphocytes at diagnosis of acquired immunodeficiency syndrome-defining and other human immunodeficiency virus-related illnesses. The Adult and Adolescent Spectrum of HIV Disease Project Group. Arch Intern Med 1995;155:1537-42.
27Boiselle PM, Tocino I, Hooley RJ, Pumerantz AS, Selwyn PA, Neklesa VP, et al. Chest radiograph interpretation of Pneumocystis carinii pneumonia, bacterial pneumonia and pulmonary tuberculosis in HIV-positive patients: Accuracy, distinguishing features, and mimics. J Thorac Imaging 1997;12:47-53.
28Hartman TE, Primack SL, Mόller NL, Staples CA. Diagnosis of thoracic complications in AIDS: Accuracy of CT. AJR Am J Roentgenol 1994;162:547-53.
29Kang EY, Staples CA, McGuinness G, Primack SL, Mόller NL. Detection and differential diagnosis of pulmonary infections and tumors in patients with AIDS: Value of chest radiography versus CT. AJR Am J Roentgenol 1996;166:15-9.
30Hirschtick RE, Glassroth J, Jordan MC, Wilcosky TC, Wallace JM, Kvale PA, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. N Engl J Med 1995;333:845-51.
31Schneider RF. Bacterial pneumonia. Semin Respir Infect 1999;14:327-32.
32Afessa B, Green B. Bacterial pneumonia in hospitalized patients with HIV infection: The Pulmonary Complications, ICU Support, and Prognostic Factors of Hospitalized Patients with HIV (PIP) Study. Chest 2000;117:1017-22.
33Selwyn PA, Pumerantz AS, Durante A, Alcabes PG, Gourevitch MN, Boiselle PM, et al. Clinical predictors of Pneumocystis carinii pneumonia, bacterial pneumonia and tuberculosis in HIV-infected patients. AIDS 1998;12:885-93.
34Fraser RS, Mόller NL, Colman N, Parι PD. General features of pulmonary infection. 4th ed. Diagnosis of Diseases of the Chest. In: Fraser's, Parι's, editors. Philadelphia, PA: W.B. Saunders; 1999. p. 701.
35McGuinness G. Changing trends in the pulmonary manifestations of AIDS. Radiol Clin North Am 1997;35:1029-82.
36Maki DD. Pulmonary infections in HIV/AIDS. Semin Roentgenol 2000;35:124-39.
37Hoover DR, Saah AJ, Bacellar H, Phair J, Detels R, Anderson R, et al. Clinical manifestations of AIDS in the era of Pneumocystis prophylaxis. Multicenter AIDS Cohort Study. N Engl J Med 1993;329:1922-6.
38Rimland D, Navin TR, Lennox JL, Jernigan JA, Kaplan J, Erdman D, et al. Prospective study of etiologic agents of community-acquired pneumonia in patients with HIV infection. AIDS 2002;16:85-95.
39Wolff AJ, O'Donnell AE. Pulmonary manifestations of HIV infection in the era of highly active antiretroviral therapy. Chest 2001;120:1888-93.
40Boiselle PM, Crans CA Jr, Kaplan MA. The changing face of Pneumocystis carinii pneumonia in AIDS patients. AJR Am J Roentgenol 1999;172:1301-9.
41Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindegren ML, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000;30:S5-14.
42Gruden JF, Huang L, Turner J, Webb WR, Merrifield C, Stansell JD, et al. High-resolution CT in the evaluation of clinically suspected Pneumocystis carinii pneumonia in AIDS patients with normal, equivocal, or nonspecific radiographic findings. AJR Am J Roentgenol 1997;169:967-75.
43Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1999;340:367-73.
44Leung AN. Pulmonary tuberculosis: The essentials. Radiology 1999;210:307-22.
45Saurborn DP, Fishman JE, Boiselle PM. The imaging spectrum of pulmonary tuberculosis in AIDS. J Thorac Imaging 2002;17:28-33.
46Long R, Maycher B, Scalcini M, Manfreda J. The chest roentgenogram in pulmonary tuberculosis patients seropositive for human immunodeficiency virus type 1. Chest 1991;99:123-7.
47Fishman JE, Saraf-Lavi E, Narita M, Hollender ES, Ramsinghani R, Ashkin D. Pulmonary tuberculosis in AIDS patients: Transient chest radiographic worsening after initiation of antiretroviral therapy. AJR Am J Roentgenol 2000;174:43-9.
48Rizzi EB, Schinina V, Bellussi A, De Santis A, Mazzuoli G, Giosuι S, et al. Pulmonary mycosis in AIDS. Eur J Radiol 2001;37:42-6.
49Wallace JM, Lim R, Browdy BL, Hopewell PC, Glassroth J, Rosen MJ, et al. Risk factors and outcomes associated with identification of Aspergillus in respiratory specimens from persons with HIV disease. Pulmonary Complications of HIV Infection Study Group. Chest 1998;114:131-7.
50Staples CA, Kang EY, Wright JL, Phillips P, Mόller NL. Invasive pulmonary aspergillosis in AIDS: Radiographic, CT, and pathologic findings. Radiology 1995;196:409-14.
51Waxman AB, Goldie SJ, Brett-Smith H, Matthay RA. Cytomegalovirus as a primary pulmonary pathogen in AIDS. Chest 1997;111:128-34.
52Cadranel J, Naccache J, Wislez M, Mayaud C. Pulmonary malignancies in the immunocompromised patient. Respiration 1999;66:289-309.
53Ognibene FP, Steis RG, Macher AM, Liotta L, Gelmann E, Pass HI, et al. Kaposi's sarcoma causing pulmonary infiltrates and respiratory failure in the acquired immunodeficiency syndrome. Ann Intern Med 1985;102:471-5.
54Wolff SD, Kuhlman JE, Fishman EK. Thoracic Kaposi sarcoma in AIDS: CT findings. J Comput Assist Tomogr 1993;17:60-2.
55Bazot M, Cadranel J, Benayoun S, Tassart M, Bigot JM, Carette MF. Primary pulmonary AIDS-related lymphoma: Radiographic and CT findings. Chest 1999;116:1282-6.
56Goedert JJ, Cotι TR, Virgo P, Scoppa SM, Kingma DW, Gail MH, et al. Spectrum of AIDS-associated malignant disorders. Lancet 1998;351:1833-9.
57Eisner MD, Kaplan LD, Herndier B, Stulbarg MS. The pulmonary manifestations of AIDS- related non-Hodgkin's lymphoma. Chest 1996;110:729-36.
58Carignan S, Staples CA, Mόller NL. Intrathoracic lymphoproliferative disorders in the immunocompromised patient: CT findings. Radiology 1995;197:53-8.
59Hsi ED, Foreman KE, Duggan J, Alkan S, Kauffman CA, Aronow HD, et al. Molecular and pathologic characterization of an AIDS-related body cavity-based lymphoma, including ultrastructural demonstration of human herpesvirus-8: A case report. Am J Surg Pathol 1998;22:493-9.
60Oza UD, Munn S. Imaging HIV/AIDS. Body cavity-based lymphoma. AIDS Patient Care STDS 2003;17:129-32.
61Morassut S, Vaccher E, Balestreri L, Gloghini A, Gaidano G, Volpe R, et al. HIV-associated human herpesvirus 8-positive primary lymphomatous effusions: Radiologic findings in six patients. Radiology 1997;205:459-63.
62Frisch M, Biggar RJ, Engels EA, Goedert JJ; AIDS-Cancer Match Registry Study Group. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001;285:1736-45.
63Aboulafia DM. The epidemiologic, pathologic, and clinical features of AIDS-associated pulmonary Kaposi's sarcoma. Chest 2000;117:1128-45.
64Kirk O, Pedersen C, Cozzi-Lepri A, Antunes F, Miller V, Gatell JM, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001;98:3406-12.
65White DA. Pulmonary complications of HIV-associated malignancies. Clin Chest Med 1996;17:755-61.
66Karp J, Profeta G, Marantz PR, Karpel JP. Lung cancer in patients with immunodeficiency syndrome. Chest 1993;103:410-3.
67Aviram G, Fishman JE, Schwartz DS. Metachronous primary carcinomas of the lung in an HIV-infected patient. AIDS Patient Care STDS 2001;15:297-300.
68Fishman JE, Schwartz DS, Sais GJ, Flores MR, Sridhar KS. Bronchogenic carcinoma in HIV-positive patients: Findings on chest radiographs and CT scans. AJR Am J Roentgenol 1995;164:57-61.
69Allen JN, Wewers MD. HIV-associated bronchiolitis obliterans organizing pneumonia. Chest 1989;96:197-8.
70Sanito NJ, Morley TF, Condoluci DV. Bronchiolitis obliterans organizing pneumonia in an AIDS patient. Eur Respir J 1995;8:1021-4.
71Dνaz F, Collazos J, Martinez E, Mayo J. Bronchiolitis obliterans in a patient with HIV infection. Respir Med 1997;91:171-3.
72Khater FJ, Moorman JP, Myers JW, Youngberg G, Sarubbi FA. Bronchiolitis obliterans organizing pneumonia as a manifestation of AIDS: Case report and literature review. J Infect 2004;49:159-64.
73Sara AG, Hamdan AJ, Hanaa B, Nawaz KA. Bronchiolitis obliterans organizing pneumonia: Pathogenesis, clinical features, imaging and therapy review. Ann Thorac Med 2008;3:67-75.
74Meng Q, Lima JA, Lai H, Vlahov D, Celentano DD, Strathdee SA, et al. Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors. Am Heart J 2002;144:642-8.
75Copur AS, Smith PR, Gomez V, Bergman M, Homel P. HIV infection is a risk factor for venous thromboembolism. AIDS Patient Care STDS 2002;16:205-9.
76Jasmer RM, Edinburgh KJ, Thompson A, Gotway MB, Creasman JM, Webb WR, et al. Clinical and radiographic predictors of the etiology of pulmonary nodules in HIV-infected patients. Chest 2000;117:1023-30.
77Piyavisetpat N, Chaowanapanja P. Radiographic manifestations of pulmonary cryptococcosis. J Med Assoc Thai 2005;88:1674-9.
78Awoyemi OB, Ige OM, Onadeko BO. Pattern of active pulmonary tuberculosis in human immunodeficiency virus seropositive adult patients in University College Hospital, Ibadan, Nigeria. Afr J Med Med Sci 2002;31:25-31.
79Batura-Gabryel H, Brajer B. Coccidioidomycosis in a 38-year-old man: A case report. Pol Arch Med Wewn 2008;118:387-90.
80Murray JF. Pulmonary complications of HIV-1 infection among adults living in Sub-Saharan Africa. Int J Tuberc Lung Dis. 2005;9:826-35.
81Gallant JE, Ko AH. Cavitary pulmonary lesions in patients infected with human immunodeficiency virus. Clin Infect Dis 1996;22:671-82.
82Jasmer RM, Gotway MB, Creasman JM, Webb WR, Edinburgh KJ, Huang L. Clinical and radiographic predictors of the etiology of computed tomography-diagnosed intrathoracic lymphadenopathy in HIV-infected patients. J Acquir Immune Defic Syndr 2002;31:291-8.
83Schlossbauer T, Schmidt GP, Bogner JR, Sing A, Reiser MF, Becker-Gaab C. Pulmonary radiological characteristics in patients with HIV infection at the time of highly active antiretroviral therapy (HAART). Eur J Med Res 2007;12:341-6.
84Shah RM, Gupta S, Angeid-Backman E, O'Donnell J. Pneumococcal pneumonia in patients requiring hospitalization: Effects of bacteremia and HIV seropositivity on radiographic appearance. AJR Am J Roentgenol 2000;175:1533-6.
85Gasparetto TD, Marchiori E, Lourenco S, Zanetti G, Vianna AD, Santos AA, et al. Pulmonary involvement in Kaposi sarcoma: Correlation between imaging and pathology. Orphanet J Rare Dis 2009;4:18.
86Godoy MC, Rouse H, Brown JA, Phillips P, Forrest DM, Mόller NL. Imaging features of pulmonary Kaposi sarcoma-associated immune reconstitution syndrome. AJR Am J Roentgenol 2007;189:956-65.
87Ikebe T, Amemiya Y, Saburi M, Ando T, Kohno K, Ogata M, et al. Rare primary effusion lymphoma associated with HHV-8 in Japan. Intern Med 2010;49:1303-6.